z-logo
open-access-imgOpen Access
Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms
Author(s) -
M-D Levin,
Jan G. den Hollander,
Bronno van der Holt,
Bart Rijnders,
M. van Vliet,
Pieter Sonneveld,
Ron H. N. van Schaik
Publication year - 2007
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkm330
Subject(s) - voriconazole , azole , cytochrome p450 , medicine , pharmacology , cyp2d6 , pharmacokinetics , metabolism , antifungal , dermatology
Voriconazole, like all other antifungals of the azole group, is potentially hepatotoxic. A large interpatient variability of liver enzyme elevations during oral or intravenous (iv) voriconazole administration is observed. This interpatient variability may be explained by differences in voriconazole metabolism because of cytochrome P450 polymorphisms. We examined the relationship between cytochrome P450 polymorphisms and hepatotoxicity in immunocompromised patients predominantly receiving oral formulations of voriconazole.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom